Cancer Stem Cell News Volume 10.13 | Apr 7 2021

2021-04-07 | CSCN 10.13

Cancer Stem Cell News by STEMCELL Technologies
Vol. 10.13 – 07 April, 2021

BCL3 Couples Cancer Stem Cell Enrichment with Pancreatic Cancer Molecular Subtypes

Scientists demonstrated that Bcl3 impacted pancreatic carcinogenesis by restraining CSC expansion and by curtailing an aggressive and metastatic tumor burden in pancreatic ductal adenocarcinoma across species.

AbstractGraphical Abstract

Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
PUBLICATIONSRanked by the impact factor of the journal

miR-146 Connects Stem Cell Identity with Metabolism and Pharmacological Resistance in Breast Cancer

Researchers showed that miR-146 was relevant for normal mammary stem cell and mammary cancer stem cell activity.
[Journal of Cell Biology]

Full Article

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia

Scientists found that leukemic stem cells in chronic myelomonocytic leukemia resided in a CD34+/CD38 fraction of the malignant clone.


C3G Downregulation Induces the Acquisition of a Mesenchymal Phenotype That Enhances Aggressiveness of Glioblastoma Cells

The authors report that C3G downregulation promoted the acquisition of a more mesenchymal phenotype that enhanced the migratory and invasive capacity of glioblastoma cells.
[Cell Death & Disease]

Full Article

Silencing PTEN in the Fallopian Tube Promotes Enrichment of Cancer Stem Cell-Like Function through Loss of PAX2

Loss of PTEN in fallopian tube epithelium led to the enrichment of CSC markers such as LGR5, WNT4, ALDH1, CD44.
[Cell Death & Disease]

Full Article

ISG15 Is Downregulated by KLF12 and Implicated in Maintenance of Cancer Stem Cell-Like Features in Cisplatin-Resistant Ovarian Cancer

Investigators identified that both ectopic wild type and nonISGylatable mutant interferon‐stimulated gene 15 (ISG15) expression inhibited CSC‐like phenotypes of cisplatin‐resistant ovarian cancer cells.
[Journal of Cellular and Molecular Medicine]

Full Article

Nitidine Chloride Suppresses Epithelial-Mesenchymal Transition and Stem Cell-Like Properties in Glioblastoma by Regulating JAK2/STAT3 Signaling

Researchers investigated the inhibitory effect of nitidine chloride on the epithelial‐mesenchymal transition process and stem cell‐like properties in glioma cells.
[Cancer Medicine]

Full Article

Tideglusib Suppresses Stem-Cell-Like Features and Progression of Osteosarcoma by Inhibiting GSK-3β/NOTCH1 Signaling

The authors found that tideglusib (TID) markedly reduced the cell viability of different osteosarcoma cell lines. Cell cycle arrest distributed in G2/M was markedly up-regulated in TID-incubated osteosarcoma cells through enhancing p21 expression levels.
[Biochemical and Biophysical Research Communications]


The AXL-PYK2-PKCα Axis as a Nexus of Stemness Circuits in TNBC

Scientists identified a clinically relevant signaling nexus mediated by AXL receptor, PYK2 and PKCα and show its impact on stemness in triple-negative breast cancer.
[Life Science Alliance]

Full Article
Explore scientific events this April with the Science Events Calendar.

Breast Cancer as an Example of Tumor Heterogeneity and Tumor Cell Plasticity during Malignant Progression

Investigators used breast cancer as an example of the origins of tumor heterogeneity and of tumor cell plasticity, as well as considering interclonal cooperativity and cell plasticity as sources of cancer cell heterogeneity.
[British Journal of Cancer]

Full Article

Cancer and Stem Cells

The authors made an attempt to scrutinize evidence that indicates the role of stem cells in tumorigenesis and metastasis, and cancer relapse.
[Experimental Biology and Medicine]


Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
[Bio-Path Holdings, Inc.]

Press Release

Turning Point Therapeutics Announces Initial Clinical Data from Phase I/II SWORD-1 Study of RET Inhibitor TPX-0046

Turning Point Therapeutics, Inc. a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today reported initial clinical data from the ongoing Phase I/II SWORD-1 study of its RET inhibitor drug candidate, TPX-0046.
[Turning Point Therapeutics, Inc. (Globe Newswire, Inc.)]

Press Release

Kite Submits Supplemental Biologics License Application to US Food and Drug Administration for Tecartus® in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Kite announced that it has submitted a supplemental Biologics License Application to FDA for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
[Kite (BusinessWire, Inc.)]

Press Release


Cancer Stem Cells: Advances in Biology and Clinical Translation

May 19 – 21, 2021

> See All Events


Postdoctoral Fellow or Research Scientist – Cell and Gene Therapy of Cancer

Rutgers University – New Brunswick, New Jersey, United States

Postdoctoral Fellowship – Breast Cancer Immunology and Immunotherapy

The University of Texas Southwestern Medical Center – Dallas, Texas, United States

Journal Editor – Blood Cancer Discovery and Cancer Immunology

American Association for Cancer Research – Boston, Massachusetts, United States

Postdoctoral Fellow – Myeloma Tumor Microenvironment

Moores Cancer Center – La Jolla, California, United States

Medicinal Chemist – Muscle-Wasting, Neurodegeneration, and Oncology

Almac – Belfast, Ireland

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter